What Not To Do When An FDA Inspector Knocks At Your Door
This article was originally published in The Tan Sheet
Executive Summary
FDA tweaks its guidance on what constitutes interference with inspections to include examples of “reasonable” explanations for delays. But industry requested other changes, including a formal process for notifying a firm of FDA’s intent to deem products adulterated due to delaying, limiting or refusing an inspection.
You may also be interested in...
Industry Worries FDA Will See Drug GMP Violations Captured By Security Cameras
A review of recent US FDA citations has industry concerned about the extent to which agency investigators may be reviewing security video archives as part of their pharmaceutical manufacturing plant inspections.
Rx Companies Push For Exemptions To Breadth Of FDA Inspections
Sterile areas, cell therapies, and security systems are just a few of the items where industry wants FDA inspector access limited without triggering a new law that would make products in a facility deemed adulterated.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.